Crispr Therapeutics AG (CRSP) Insider Trading
- $27,833,805.86
- $313,622,936.43
- Oct. 14, 2024
- Samarth Kulkarni
Trader Name | Date | Title | Amount | Price | Type | Total Value |
---|---|---|---|---|---|---|
Oct. 14, 2024 | General Counsel | 1,089 | $46.28 | Sell | $50,398.92 | |
Oct. 14, 2024 | CEO | 4,293 | $46.28 | Sell | $198,680.04 | |
June 21, 2024 | COO | 3,366 | $56.09 | Sell | $188,798.94 | |
April 15, 2024 | CEO | 19,582 | $59.91 | Sell | $1,173,157.62 | |
March 15, 2024 | CEO | 20,000 | $72.48 | Sell | $1,449,600.00 | |
March 15, 2024 | CFO | 3,524 | $72.69 | Sell | $256,159.56 | |
March 11, 2024 | CEO | 9,802 | $78.26 | Sell | $767,104.52 | |
March 11, 2024 | General Counsel | 2,801 | $78.26 | Sell | $219,206.26 | |
Feb. 20, 2024 | CEO | 6,370 | $79.67 | Sell | $507,497.90 | |
Feb. 20, 2024 | General Counsel | 1,913 | $79.67 | Sell | $152,408.71 | |
Feb. 15, 2024 | CEO | 20,000 | $80.36 | Sell | $1,607,200.00 | |
Jan. 29, 2024 | CEO | 50,000 | $60.51 | Sell | $3,025,500.00 | |
Jan. 16, 2024 | CEO | 20,000 | $62.50 | Sell | $1,250,000.00 | |
May 30, 2023 | CEO | 25,000 | $64.88 | Sell | $1,622,000.00 | |
April 25, 2023 | CEO | 25,000 | $50.67 | Sell | $1,266,750.00 | |
March 29, 2023 | CEO | 25,000 | $44.46 | Sell | $1,111,500.00 | |
Feb. 27, 2023 | CEO | 25,000 | $48.25 | Sell | $1,206,250.00 | |
Jan. 27, 2023 | CEO | 25,000 | $51.47 | Sell | $1,286,750.00 | |
Dec. 28, 2022 | CEO | 25,000 | $40.93 | Sell | $1,023,250.00 | |
Nov. 28, 2022 | CEO | 25,000 | $54.03 | Sell | $1,350,750.00 | |
Oct. 26, 2022 | CEO | 25,000 | $54.81 | Sell | $1,370,250.00 | |
Sept. 28, 2022 | CEO | 25,000 | $64.61 | Sell | $1,615,250.00 | |
Aug. 29, 2022 | CEO | 25,000 | $66.84 | Sell | $1,671,000.00 | |
July 27, 2022 | CEO | 25,000 | $75.91 | Sell | $1,897,750.00 | |
June 29, 2022 | CEO | 25,000 | $61.59 | Sell | $1,539,750.00 | |
Aug. 6, 2021 | CFO | 25,000 | $138.52 | Sell | $3,463,000.00 | |
Aug. 4, 2021 | CEO | 1,500 | $125.02 | Sell | $187,530.00 | |
July 19, 2021 | Director | 10,000 | $126.43 | Sell | $1,264,300.00 | |
June 30, 2021 | President | 25,000 | $165.00 | Sell | $4,125,000.00 | |
June 28, 2021 | Director | 20,375 | $152.48 | Sell | $3,106,780.00 | |
June 21, 2021 | President | 25,000 | $128.62 | Sell | $3,215,500.00 | |
June 15, 2021 | CEO | 30,000 | $126.43 | Sell | $3,792,900.00 | |
June 11, 2021 | Director | 10,000 | $126.61 | Sell | $1,266,100.00 | |
March 22, 2021 | Director | 30,374 | $132.37 | Sell | $4,020,606.38 | |
Jan. 19, 2021 | General Counsel | 27,500 | $204.94 | Sell | $5,635,850.00 | |
Jan. 15, 2021 | COO | 25,000 | $215.20 | Sell | $5,380,000.00 | |
Jan. 15, 2021 | CEO | 20,000 | $213.67 | Sell | $4,273,400.00 | |
Dec. 21, 2020 | VP | 23,551 | $149.23 | Sell | $3,514,515.73 | |
Dec. 16, 2020 | Director | 7,648 | $148.95 | Sell | $1,139,169.60 | |
Dec. 10, 2020 | CEO | 20,000 | $142.29 | Sell | $2,845,800.00 | |
Dec. 10, 2020 | Director | 33,000 | $143.35 | Sell | $4,730,550.00 | |
Dec. 7, 2020 | Director | 171,004 | $154.53 | Sell | $26,425,248.12 | |
Nov. 30, 2020 | President | 100,000 | $125.00 | Sell | $12,500,000.00 | |
Sept. 18, 2020 | Director | 3,035 | $86.87 | Sell | $263,650.45 | |
Sept. 16, 2020 | Director | 8,965 | $86.98 | Sell | $779,775.70 | |
Sept. 14, 2020 | Director | 1,155 | $84.89 | Sell | $98,047.95 | |
Sept. 10, 2020 | Director | 22,845 | $85.36 | Sell | $1,950,049.20 | |
Sept. 1, 2020 | President | 25,000 | $92.62 | Sell | $2,315,500.00 | |
Sept. 1, 2020 | CFO | 12,000 | $92.26 | Sell | $1,107,120.00 | |
Sept. 1, 2020 | Director | 60,000 | $92.51 | Sell | $5,550,600.00 |
Insiders are both buying and selling Crispr Therapeutics AG stock.
The insider traders at Crispr Therapeutics AG are: Samarth Kulkarni, Rodger Novak, Kurt Von Emster, Bradley J Phd Bolzon, Corp /De/ Celgene, Tyler Dylan-Hyde, Pablo J Cagnoni, Thomas Woiwode, Lawrence Otto Klein, Vertex Pharmaceuticals (Europe, James R Kasinger, Michael John Tomsicek, Julianne Bruno, Simeon George, James R. Kasinger, Tony W Ho, Tony W. Ho, Bradley J. Phd Bolzon, Versant Venture Capital V, L.P, Raju Prasad, and Aktiengesellschaft Bayer
The most active insider trader at Crispr Therapeutics AG is Samarth Kulkarni with 32 trades.
Kurt Von Emster has sold the most Crispr Therapeutics AG stock with a total value of $68,130,025.01.
Aktiengesellschaft Bayer has bought the most Crispr Therapeutics AG stock with a total value of $23,999,976.00.
The most recent insider trade for Crispr Therapeutics AG was on Oct. 14, 2024.
The single biggest insider buy for Crispr Therapeutics AG was from Aktiengesellschaft Bayer with a total value of $11,999,988.00 on Jan. 5, 2018.
The single biggest insider sell for Crispr Therapeutics AG was from Kurt Von Emster with a total value of $35,353,500.00 on May 14, 2018.